Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. (Q51021033)
Jump to navigation
Jump to search
scientific article published on 30 April 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. |
scientific article published on 30 April 2013 |
Statements
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. (English)
1 reference
Armando Santoro
1 reference
Philippe Rougier
1 reference
Hanno Riess
1 reference
Robert Manges
1 reference
Petr Karasek
1 reference
Yves Humblet
1 reference
Carlo Barone
1 reference
Sylvie Assadourian
1 reference
Laurence Hatteville
1 reference
Philip A Philip
1 reference
30 April 2013
1 reference
49
1 reference
12
1 reference
2633-2642
1 reference